The 11 references in paper Н. Воробьёва М., Е. Панченко П. (2014) “ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ДЛИТЕЛЬНОЙ ТЕРАПИИ ДАБИГАТРАНОМ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ” / spz:neicon:aterotromboz:y:2014:i:2:p:2-10

1
Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation — Executive Summary: A Report of the American College of Cardiology Committee for Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) [published correction appears in J. Am. Coll. Cardiol.,2007, 50: 562]. J. Am. Coll. Cardiol., 2006, 48: 854–906.
(check this in PDF content)
2
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.,2007, 146: 857–867.
(check this in PDF content)
3
Albers GW, Sherman DG, Gress DR. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann. Neurol.,1991, 30: 511–518.
(check this in PDF content)
4
Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate — a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost.,2010, 103: 1116–1127.
(check this in PDF content)
5
Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.,2009, 361: 1139–1151.
(check this in PDF content)
6
Connolly SJ, Wallentin L, Ezekowitz MD et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation,2013, 128: 237–243.
(check this in PDF content)
7
Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N. Engl. J. Med.,2013, 368: 1272–1274.
(check this in PDF content)
8
Patel MR, Mahaffey KW, Garg J et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med.,2011, 365: 883-891.
(check this in PDF content)
9
Granger CB, Alexander JH, McMurray JJV et al. For the ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med.,2011, 365: 981–992.
(check this in PDF content)
10
IMS, National Prescription Audit (NPA) and IMS, Vector One®: Total Patient Tracker (TPT) Databases. October 2010December 2013. Extracted February 2014.
(check this in PDF content)
11
FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. http://www.fda.gov/Drugs/DrugSafety/ ucm396470.htm. ТАБЛИЦА 5.Частота неблагоприятных исходов у больных ФП, принимавших дабигатран
(check this in PDF content)